Zhende Medical(SH:603301)2024-04-26 09:17Financial Performance - The company's operating revenue for Q1 2024 was ¥963,887,437.65, representing a decrease of 25.88% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥73,397,631.01, down 49.89% year-on-year[5]. - Basic and diluted earnings per share were both ¥0.28, reflecting a decrease of 49.09% compared to the same period last year[5]. - Total operating revenue for Q1 2024 was ¥963,887,437.65, a decrease of 25.9% compared to ¥1,300,476,798.62 in Q1 2023[17]. - Net profit for Q1 2024 was ¥75,230,110.17, a decline of 49.1% from ¥147,985,140.95 in Q1 2023[18]. - Earnings per share for Q1 2024 were ¥0.28, compared to ¥0.55 in Q1 2023[19]. Profitability and Margins - The gross profit margin for the main business was 34.90%, with a 6.19 percentage point increase year-on-year when excluding isolation protective products[8]. - The weighted average return on equity decreased by 1.25 percentage points to 1.36%[5]. - The company reported a significant decline in revenue from isolation protective products, which amounted to ¥51,153,300, a decrease of 87.66% year-on-year[8]. Cash Flow and Operating Activities - Cash flow from operating activities increased by ¥231,668,400 compared to the previous year, mainly due to reduced payments for employee wages and taxes[8]. - In Q1 2024, the cash inflow from operating activities was CNY 1,048,332,483.77, a decrease of 25% compared to CNY 1,397,604,503.80 in Q1 2023[20]. - The net cash flow from operating activities turned positive at CNY 26,297,173.49, compared to a negative CNY 205,371,184.05 in the same period last year[22]. - Cash outflow for operating activities decreased to CNY 1,022,035,310.28, down 36% from CNY 1,602,975,687.85 in Q1 2023[22]. Assets and Liabilities - Total assets at the end of Q1 2024 were ¥8,005,323,343.11, an increase of 10.16% from the end of the previous year[6]. - The company's total liabilities increased to ¥2,297,225,449.44 in Q1 2024 from ¥1,662,319,359.19 in Q1 2023, representing a growth of 38.2%[16]. - Non-current liabilities rose to ¥959,902,362.67 in Q1 2024, up from ¥490,023,761.75 in Q1 2023, marking an increase of 96.0%[16]. - The company's total equity increased to ¥5,708,097,893.67 in Q1 2024 from ¥5,604,400,315.51 in Q1 2023, reflecting a growth of 1.8%[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 25,896[10]. - The company reported a pledge of 23,547,880 shares by its largest shareholder, Zhejiang Zhend Medical Holdings Co., Ltd., which holds 49.82% of the shares[12]. - The company has no significant changes in the participation of major shareholders in margin financing and securities lending activities[12]. Research and Development - Research and development expenses decreased to ¥29,493,825.79 in Q1 2024 from ¥42,093,960.50 in Q1 2023, a reduction of 30.0%[17]. Other Income and Expenses - Other income for Q1 2024 was ¥11,704,234.34, significantly higher than ¥4,083,356.56 in Q1 2023, indicating an increase of 187.5%[18]. - The company recorded non-operating income and expenses totaling -¥1,298,414.20, after accounting for tax and minority interests[8]. - The company reported a fair value change loss of ¥1,841,014.94 in Q1 2024, compared to a gain of ¥14,606,416.45 in Q1 2023[18]. Inventory and Current Assets - The company's inventory decreased to CNY 770,411,652.87 from CNY 800,806,476.52, showing a decline of about 3.8%[14]. - Total current assets increased to CNY 3,290,568,290.28 from CNY 2,719,806,144.11, reflecting a growth of approximately 21%[14]. - The company's accounts receivable increased to CNY 559,536,019.08 from CNY 539,646,098.58, which is an increase of about 3.7%[13]. Financing Activities - Cash inflow from financing activities increased significantly to CNY 1,127,760,000.00, compared to CNY 534,900,000.00 in the previous year, marking a 111% increase[22]. - The net cash flow from financing activities was CNY 698,234,792.57, up from CNY 474,244,778.31 in Q1 2023[22].